High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
Abstract Background Considering the recent advancements in the treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2), we aimed to examine inter-laboratory variability in the assessment of HER2-low breast cancer across all Danish pathology departments. Meth...
Main Authors: | Kåre Nielsen, Michael Sode, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13058-023-01739-9 |
Similar Items
-
Correlation of the HER-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer
by: Svjetlana Radović, et al.
Published: (2005-02-01) -
Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01) -
A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
by: Fnu Amisha, et al.
Published: (2023-05-01) -
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
by: Huizi Lei, et al.
Published: (2023-06-01) -
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
by: Elham Sajjadi, et al.
Published: (2023-04-01)